PMID- 33305638
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20211216
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 17
IP  - 1
DP  - 2021 Jan
TI  - Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and 
      intravenous infliximab in patients with rheumatoid arthritis: a systematic 
      literature review and meta-analysis.
PG  - 85-99
LID - 10.1080/1744666X.2020.1858803 [doi]
AB  - OBJECTIVES: There are few comparative data for tumor necrosis factor inhibitors 
      in patients with rheumatoid arthritis (RA). METHODS: Historical data for 
      reference product/biosimilar intravenous infliximab, or adalimumab and 
      etanercept, were pooled and compared with phase 3 study results for a 
      subcutaneous (SC) formulation of the infliximab biosimilar CT-P13, in a 
      systematic review and meta-analysis (PROSPERO: CRD42019149621). RESULTS: The 
      authors identified 13 eligible controlled trials that randomized over 5400 
      participants to prespecified treatments of interest. Comparison with pooled 
      historical data suggested a numerical advantage for CT-P13 SC over intravenous 
      infliximab for almost every prespecified efficacy outcome evaluated, including 
      Disease Activity Score in 28 joints (C-reactive protein/erythrocyte sedimentation 
      rate), Clinical/Simplified Disease Activity Index scores, American College of 
      Rheumatology responses, and multiple measures of disease remission and low 
      disease activity; for the majority of outcomes, there was no overlap in 95% 
      confidence intervals between groups. A numerical advantage for CT-P13 SC was also 
      observed for safety outcomes (adverse events, infections, and discontinuations). 
      Similar, but less marked, trends were observed for comparison with historical 
      efficacy and safety data for adalimumab/etanercept. CONCLUSION: CT-P13 SC offers 
      an improved or similar benefit-to-harm ratio compared with infliximab 
      (intravenous) and adalimumab/etanercept, for the treatment of moderate-to-severe 
      RA.
FAU - Caporali, Roberto
AU  - Caporali R
AUID- ORCID: 0000-0001-9300-6169
AD  - Department of Clinical Sciences and Community Health, Research Centre for Adult 
      and Pediatric Rheumatic Diseases, University of Milan, ASST Pini-CTO, Milan, 
      Italy.
FAU - Allanore, Yannick
AU  - Allanore Y
AD  - Rheumatology Department, Hopital Cochin, Paris Descartes University, Paris, 
      France.
FAU - Alten, Rieke
AU  - Alten R
AUID- ORCID: 0000-0002-3395-4412
AD  - Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, University 
      Medicine Berlin, Berlin, Germany.
FAU - Combe, Bernard
AU  - Combe B
AUID- ORCID: 0000-0003-4002-1861
AD  - Department of Rheumatology, CHU, CHU Montpellier, Montpellier University, 
      Montpellier, France.
FAU - Durez, Patrick
AU  - Durez P
AD  - Rheumatology, Cliniques Universitaires Saint-Luc - Universite Catholique De 
      Louvain - Institut De Recherche Experimentale Et Clinique (IREC), Brussels, 
      Belgium.
FAU - Iannone, Florenzo
AU  - Iannone F
AD  - Rheumatology Unit, Department of Emergency and Organ Transplantation, Universita 
      Degli Studi Di Bari Aldo Moro, Bari, Italy.
FAU - Nurmohamed, Mike T
AU  - Nurmohamed MT
AD  - Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, 
      Amsterdam, The Netherlands.
AD  - Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU 
      University Medical Center, Amsterdam, The Netherlands.
FAU - Lee, Sang Joon
AU  - Lee SJ
AD  - Celltrion, Inc. Incheon, Republic of Korea.
FAU - Kwon, Taek Sang
AU  - Kwon TS
AD  - Celltrion Healthcare, Incheon, Republic of Korea.
FAU - Choi, Jean Soo
AU  - Choi JS
AD  - Celltrion Healthcare, Incheon, Republic of Korea.
FAU - Park, Gahee
AU  - Park G
AD  - Celltrion, Inc. Incheon, Republic of Korea.
FAU - Yoo, Dae Hyun
AU  - Yoo DH
AUID- ORCID: 0000-0002-0643-4008
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
LA  - eng
SI  - figshare/10.6084/m9.figshare.13490888.v1
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20201228
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - *Adalimumab/adverse effects/therapeutic use
MH  - Administration, Cutaneous
MH  - Administration, Intravenous
MH  - *Antirheumatic Agents/administration & dosage/adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - *Biosimilar Pharmaceuticals/administration & dosage/adverse effects/therapeutic 
      use
MH  - *Etanercept/adverse effects/therapeutic use
MH  - Humans
MH  - Infliximab/administration & dosage/*adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adalimumab
OT  - CT-P13
OT  - biosimilar
OT  - etanercept
OT  - infliximab
OT  - rheumatoid arthritis
EDAT- 2020/12/12 06:00
MHDA- 2021/12/17 06:00
CRDT- 2020/12/11 08:37
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2020/12/11 08:37 [entrez]
AID - 10.1080/1744666X.2020.1858803 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2021 Jan;17(1):85-99. doi: 
      10.1080/1744666X.2020.1858803. Epub 2020 Dec 28.